{"id":"taurolock-hep500","safety":{"commonSideEffects":[{"rate":null,"effect":"Local catheter site reactions"},{"rate":null,"effect":"Catheter dysfunction"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Taurolidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and prevents biofilm formation on catheter surfaces, while heparin (500 IU/mL) provides anticoagulant activity to prevent catheter thrombosis. This dual mechanism reduces both infectious and thrombotic complications associated with long-term central venous catheter use.","oneSentence":"TauroLock Hep500 is a catheter lock solution that prevents bacterial biofilm formation and thrombosis in central venous catheters through a combination of taurolidine and heparin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:23:38.808Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of catheter-related bloodstream infections (CRBSI) in patients with central venous catheters"},{"name":"Prevention of catheter thrombosis in central venous catheters"}]},"trialDetails":[{"nctId":"NCT01243710","phase":"PHASE4","title":"Taurolidine in Haemodialysis Catheter Related Bacteraemia","status":"COMPLETED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2010-08","conditions":"Renal Dialysis, Catheter-Related Infections","enrollment":27},{"nctId":"NCT03539718","phase":"PHASE4","title":"Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2018-05-15","conditions":"Hemodialysis Catheter Infection, Thrombosis; Dialysis Catheter","enrollment":60},{"nctId":"NCT02036255","phase":"PHASE3","title":"Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2015-05","conditions":"Patency, Infection","enrollment":68},{"nctId":"NCT02789501","phase":"PHASE4","title":"Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-01","conditions":"Catheter Infections, End-stage Renal Disease","enrollment":106},{"nctId":"NCT02868697","phase":"PHASE4","title":"Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2013-11","conditions":"Hemodialysis, Tunneled Catheter, Qatar","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"(TauroLock Hep500)","genericName":"(TauroLock Hep500)","companyName":"Hamad Medical Corporation","companyId":"hamad-medical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TauroLock Hep500 is a catheter lock solution that prevents bacterial biofilm formation and thrombosis in central venous catheters through a combination of taurolidine and heparin. Used for Prevention of catheter-related bloodstream infections (CRBSI) in patients with central venous catheters, Prevention of catheter thrombosis in hemodialysis and parenteral nutrition patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}